You are on Trendlyne United States. Click here to go to India website or make United States as your default

Takeda Pharmaceutical Co - ADR XNYS: TAK

Takeda Pharmaceutical Co - ADR Live Share Price Today, Share Analysis and Chart

15.18 0.17 (1.13%)

New 52W High today

1.3M XNYS Volume

XNYS 17 Mar, 2025 5:30 PM (EDT)

Takeda Pharmaceutical Co -... Key Metrics

Select
All financials are in JPY Million and price data in USD
VIEW MORE
High Financial Strength
66.7 / 100
Mid Valuation
44.2 / 100
Technically Neutral
58.1 / 100
Mid-range Performer These stocks are with strong quality. Their reasonable financials and technical aspects successfully gather investor's interest. View Similar Embed DVM

Takeda Pharmaceutical Co -... Live Price Chart

Switch to TradingView
Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Created with Highcharts 7.2.2Mar '22Mar '23Mar '24Mar '25Mar '2625k27.5k30k32.5k35kActual RevenueAvg. Estimate
Hit

Takeda Pharmaceutical Co - ADR's Revenue was higher than average estimate 3 times in past 3 years

EPS forecast

Current EPS
0.3
Avg. Estimate
0.3
Low Estimate
0.3
High Estimate
0.3
Current EPS
Avg. Estimate
Miss

EPS is expected to reduce by 6.7% in FY25

Consensus Recommendation

4 ANALYST Recommendations
BUY

Created with Highcharts 7.2.21Hold3Strong Buy

The consensus recommendation from 4 analysts for Takeda Pharmaceutical Co - ADR is BUY

Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get

Takeda Pharmaceutical Co -... Stock Analysis

Takeda Pharmaceutical Co -... stock analysis with key metrics, changes, and trends.

Takeda Pharmaceutical Co -... MetricVALUECHANGE %TRENDANALYSIS
Annual Revenue$4,263,762 M5.87%positive

Annual Revenue rose 5.87%, in the last year to $4,263,762 M. Its sector's average revenue growth for the last fiscal year was 7.47%.

Annual Net Profit$144,067 M54.56%negative

Annual Net Profit fell 54.56% in the last year to $144,067 M. Its sector's average net profit growth for the last fiscal year was -32.47%.

Price to Earning Ratio34.24-negative

Price to Earning Ratio is 34.24, higher than its sector PE ratio of 4.3.

Stock Price$15.184.91%negative

Stock Price rose 4.91% and underperformed its sector by 4.45% in the past year.

Quarterly Revenue$1,144,124 M2.96%positive

Quarterly Revenue rose 2.96% YoY to $1,144,124 M. Its sector's average revenue growth YoY for the quarter was 5.97%.

Quarterly Net profit$23,789 M77.5%negative

Quarterly Net profit fell 77.5% YoY to $23,789 M. Its sector's average net profit growth YoY for the quarter was -47.43%.

Debt to Equity Ratio0.67-positive

Debt to Equity Ratio of 0.67 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

Return on Equity(ROE)2.11 %2.11%negative

Return on Equity(ROE) for the last financial year was 2.11%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

Mutual Fund Holding1.15 %-0.04%negative

Mutual Fund Holding decreased by 0.04% in the last quarter to 1.15.

Interest Coverage Ratio1.44-neutral

Interest Coverage Ratio is 1.44, in the normal range of 1 to 1.5.

Institutional Holding2.32 %-0.1%negative

Institutional Holding decreased by 0.1% in the last quarter to 2.32.

VIEW LESS


Loading data..

Takeda Pharmaceutical Co - ADR - Company Profile

What does Takeda Pharmaceutical Co - ADR do?

Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.3 trillion in fiscal 2023. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the US, 20% from Japan, 20% from Europe and Canada.

Takeda Pharmaceutical Co - ADR Management structure

All Gross Remunerations are in JPY
Mr. Christophe Weber
Director, President and Chief Executive Officer; Head of Global Business of Takeda Pharmaceuticals U. S. A. , Inc.
1.7 B
2024
Gross Remuneration
Year
Mr. Costa Saroukos
Director and Chief Financial Officer
811 M
2024
Gross Remuneration
Year
Mr. Masato Iwasaki,, PhD
Director and Director, Japan General Affairs
120 M
2024
Gross Remuneration
Year
Mr. Andrew S. Plump, M.D.
Director and President, Research and Development
12 M
2024
Gross Remuneration
Year
Ms. Elaine Shannon
Global Quality Officer
-
2024
Gross Remuneration
Year
Ms. Asuka Miyabashira
President, Japan Pharma Business Unit
-
2024
Gross Remuneration
Year

Takeda Pharmaceutical Co - ADR Board of directors

All Gross Remunerations are in JPY
Ms. Emiko Higashi
Independent Director
49 M
2024
Gross Remuneration
Year
Mr. Michel Orsinger
Independent Director
46 M
2024
Gross Remuneration
Year
Mr. Ian T. Clark
Independent Director
44 M
2024
Gross Remuneration
Year
Dr. Steven Gillis, Pd.D
Independent Director
44 M
2024
Gross Remuneration
Year
Mr. Olivier Bohuon
Independent Director
43 M
2024
Gross Remuneration
Year
Mr. Koji Hatsukawa
Independent Director
43 M
2024
Gross Remuneration
Year

Takeda Pharmaceutical Co - ADR FAQ

How is Takeda Pharmaceutical Co - ADR today?
Takeda Pharmaceutical Co - ADR today is trading in the green, and is up by 1.13% at 15.18.
Takeda Pharmaceutical Co - ADR is currently trading up 1.13% on an intraday basis. In the past week the stock rose 0.93%. stock has been up 13.62% in the past quarter and rose 4.91% in the past year. You can view this in the overview section.